药明合联业绩与股价狂飙、药明康德却三度减持 2025年D&M资本支出将翻番或是重要原因

每日经济新闻
03 Apr

每经记者 陈星 每经编辑 马子卿4月2日,药明康德(SH603259,股价63.52,市值1834亿元)公告再度减持药明合联(HK02268,股价41.150港元,市值424.22亿港元)股份。这是自去年11月以来,公司第三次减持持有的药明合联股份。通过减持,药明康德总计回笼资金超45亿港元。仅在2025年,减持药明合联股票就将为药明康德增厚净利润约31.44亿元。《每日经济新闻》记者注意到...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10